Drug-induced thrombocytopenia induced by trastuzumab: A special challenge in a curable disease

Annals of Oncology

Volumn 20, Issue 9, 2009, Pages 1607-1608

  Jara Sanchez C ^a   Olier Garate C ^a   Garcia Donas Jimenez J ^a   Penalver Parraga J ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN; STEROID RECEPTOR; TRASTUZUMAB;

ADULT; APOCRINE CARCINOMA; ARTICLE; BONE MARROW BIOPSY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER STAGING; CASE REPORT; FEMALE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; INTRADUCTAL CARCINOMA; LOADING DRUG DOSE; LYMPH NODE DISSECTION; PARTIAL MASTECTOMY; PETECHIA; PRIORITY JOURNAL; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TUMOR VOLUME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; TAXOIDS; THROMBOCYTOPENIA;

EID: 69849094640     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp374     Document Type: Article

References (13)

1. Curtis BR, Kaliszewski J, Marques MB et al. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 2006; 81: 193-198.
2. Beg MS, Komrokji RS, Ahmed K, Safa MM. Oxaliplatin-induced immune mediated thrombocytopenia. Cancer Chemother Pharmacol 2008; 62(5): 925-927.
3. Bozec L, Bierlin P, Fromont P et al. Irinotecan-induced immune thrombocytopenia. Ann Oncol 1998; 9(4): 453-455.
4. Aster R. Drug-induced thrombocytopenia. In Michelson AD (ed), Platelets. New York: Academic Press 2007; 887-902.
5. Cathomas R, Goldhirsch A, Von Moos R. Drug induced thrombocytopenia. Correspondence. N Engl J Med 2007; 357: 1870-1871.
6. Parikh O, Neave F, Palmieri C. Severe thrombocytopenia induced by a single infusion of trastuzumab. Clin Breast Cancer 2008; 8(3): 285-286.
7. Mazzucconi MG. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: A GIMEMA experience. Blood 2007; 109: 1401-1407.
8. Baselga J, Carbonell X, Castañeda-Soto NJ et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23: 2162-2171.
9. George JN, Raskob GE, Shah SR et al. Drug-induced thrombocytopenia: A systematic review of published case reports. Ann Intern Med 1998; 129: 886-890.
10. Bedard PL, Piccart-Gebhart MJ. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin Breast Cancer 2008; 8 (Suppl 4): S157-S165.
11. Curtis BR, Divgi A, Garritty M, Aster RH. Delayed thrombocytopenia after treatment with abciximab: A distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004; 2: 985-992.
12. Christie DJ, Weber RW, Mullen PC et al. Structural features of the quinidine and quinine molecules necessary for binding of drug-induced antibodies to human platelets. J Lab Clin Med 1984; 104: 730-740.
13. Sledge GW. Advances in HER2-positive breast cancer. Clin Adv Hematol Oncol 2008; 6: 98-100.